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Background: Visceral fat deposition and its associated atherogenic complications are mediated by glucocorticoids.
Cardiac visceral fat comprises mediastinal adipose tissue (MAT) and epicardial adipose tissue (EAT), and MAT is a
potential biomarker of risk for obese patients.
Aim: Our objective was to evaluate the role of EAT and MAT 11beta-hydroxysteroid dehydrogenase type 1
(11β-HSD-1) and glucocorticoid receptor (GCR) expression in comparison with subcutaneous adipose tissue (SAT)
in the development of coronary atherosclerosis in obese patients with coronary artery disease (CAD), and to assess
their correlations with CD68 and fatty acids from these tissues.
Methods and results: Expression of 11β-HSD-1 and GCR was measured by qRT-PCR in EAT, MAT and SAT of
thirty-one obese patients undergoing coronary artery bypass grafting due to CAD (obese CAD group) and sixteen
obese patients without CAD undergoing heart valve surgery (controls). 11β-HSD-1 and GCR expression in MAT were
found to be significantly increased in the obese CAD group compared with controls (p < 0.05). In the obese CAD
group, 11β-HSD-1 and GCR mRNA levels were strongly correlated in MAT. Stearidonic acid was significantly
increased in EAT and MAT of the obese CAD group and arachidonic acid was significantly expressed in MAT of the
obese male CAD group (p < 0.05).
Conclusions: We report for the first time the increased expression of 11β-HSD-1 and GCR in MAT compared with
EAT and SAT, and also describe the interrelated effects of stearidonic acid, HOMA-IR, plasma cortisol and GCR mRNA
levels, explaining 40.2% of the variance in 11β-HSD-1 mRNA levels in MAT of obese CAD patients. These findings
support the hypothesis that MAT contributes locally to the development of coronary atherosclerosis via
glucocorticoid action.
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In obesity, fat depots localized around the heart are
reported to contribute to the pathogenesis of coronary
artery disease (CAD) [1-3]. Epicardial adipose tissue
(EAT) generates various bioactive molecules which sig-
nificantly affect cardiac function, and their association
with the severity of CAD was has also been reported
[2,4]. Human and animal studies have demonstrated
EAT is located near to the arteries and that segments
of an artery surrounded by EAT develop atheroscler-
osis faster than the intra-myocardial segments of the
same artery [5]. Despite the fact that mediastinal adi-
pose tissue (MAT, also known as paracardial adipose
tissue or intrathoracic adipose tissue) is not close to
the coronary arteries, it constitutes the majority of car-
diac fat. Interestingly, a recent magnetic resonance im-
aging (MRI) study has shown that MAT contributes to
the development of cardiovascular diseases [6,7]. More-
over, the presence of an association between cardiac
visceral fat mass (epicardial and mediastinal) and insu-
lin resistance, blood pressure and CAD has been
demonstrated by MRI and computed tomography (CT)
scans [3,8,9]. Visceral fat depots are recognized as a
rich source of 11beta-hydroxysteriod dehydrogenase
type 1(11β-HSD-1) and adipokines such as adiponec-
tin, resistin, inflammatory cytokines, glucocorticoids
and free fatty acids (FFA) [10,11]. Their important role
in the pathogenesis of visceral obesity has also been
demonstrated by clinical and animal studies [12-17].
The deposition and distribution of visceral fat, and
associated atherogenic complications, are known to be
mediated by glucocorticoids and 11β-HSD-1 activity,
whilst an increased level of cortisol is also reported in
obese subjects [18]. This increased cortisol, produced
through 11β-HSD-1, in turn feeds back on visceral fat
to stimulate 11β-HSD-1 and to cause additional vis-
ceral fat production. In addition, the expression level
of glucocorticoid receptor in intra-abdominal fat and
epicardial fat were shown to be upregulated in obesity
and CAD leading to an amplification of glucocorticoid
signaling and the expansion of these fat depots [19,20].
The question of whether the cardiac visceral adipose
tissues (EAT and MAT) and SAT have similar
11β-HSD-1 and glucocorticoid receptor (GCR) gene
expression patterns in obese patient with CAD (obese
CAD group) and non-CAD (controls) has not been
addressed before. Therefore, we aimed to compare the
expression of the two major determinants of gluco-
corticoid action; 11β-HSD-1, known as the cortisol re-
generating enzyme, and GCR in two different cardiac
visceral fat depots in addition to the subcutaneous fat
depots of the obese CAD group and controls. This
was performed in order to evaluate their contribution
to the development of the coronary atherosclerosis andto study their association with metabolic and clinical
parameters and fatty acid profiles from these tissues.
Methods
Subjects
There were thirty-one obese patients undergoing coron-
ary artery bypass grafting (CABG) due to CAD (obese
CAD group) and sixteen obese patients without CAD
undergoing heart valve surgery (controls). All patients
were evaluated by a multidisciplinary team and met the
appropriate criteria for the operation. All the patients
with CAD had angiographic evidence of critical coronary
atherosclerosis involving three vessels deemed necessary
for an elective CABG surgery. Subjects with any history
of HIV, viral hepatitis, cancer, collagen diseases, endocri-
nopathies, secondary hypertension and diabetic microan-
giopathic complications were excluded from the study.
None of the female patients were on birth control pills or
postmenopausal hormone replacement. Controls did not
show any atherosclerotic lesions in their coronary angio-
graphies. A detailed history was obtained, and physical
examination was done for each subject. Blood pressure,
height, weight, hip and waist circumference were
recorded. BMI was calculated for all the patients as
weight in kilograms divided by the square of height in
meters. Obesity was identified according to BMI using
the National Institutes of Health (NIH) criteria. The
mean BMI of our study group, which comprised of obese
CAD group and controls, was 30.2 kg/cm2. The cut-off
points of waist circumference for cardiovascular disease
risk were 87 cm for men and 83 cm for women, as
defined by the criteria of TEKHARF (Turkish Adults
Heart Disease and Risk Factors Study) [21]. Diagnosis of
hypertension was based on a resting systolic or diastolic
blood pressure >140 or >90 mmHg respectively, or
current use of antihypertensive therapy. Dyslipidemia
was defined as low-density lipoprotein (LDL) cholesterol
≥3 mmol/l or the use of hypolipidemic agents. All
patients had normal dietary regimes at least three days
before taking blood samples. Plasma and tissue samples
were obtained after 10 hours (overnight) fasting. Fasting
venous blood samples were separated as serum, plasma
and cellular portions and stored at −80°C for biochemical
analyses. EAT, MAT and SAT were collected during
CABG and heart valve surgeries in the form of biopsy.
Tissue samples were then immediately frozen in liquid
nitrogen and stored at −80°C prior to total RNA prepar-
ation and fatty acid analysis. Oral antidiabetics, including
metformin, and lipid lowering drugs which may interfere
with adipocytokine gene expression were stopped 3 days
before blood and tissue sample collection. None of the
patients were treated with thiazolidinediones. All patients
gave their written informed consent. The project was
approved by the local ethics committee of Istanbul
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with the ethical standards formulated in the Helsinki
Declaration.Biochemical measurements
Serum total cholesterol and high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, triglycerides (TG), fasting glucose, fasting insulin
and morning plasma cortisol were measured by routine
assays in the hospital laboratory. All analyses were per-
formed on Cobas 6000 instrument (Roche). Insulin re-
sistance was evaluated using the homeostatic model
assessment of insulin resistance (HOMA-IR = fasting
glucose [mmol/L]x fasting insulin[uU/mL]/22.5). A
HOMA-IR value greater than 2.24 as suggested by the
TEKHARF study was taken as the cut-off point for insu-
lin resistance for the study group [22]. Body fat amount
was assessed by the bioelectrical impedance technique
(MC 180, TANITA Corporation, Tokyo, Japan). Volu-
metric measurement of epicardial and subcutaneous fat
were obtained by multislice computed tomography
(LightSpeed VCT 64, GE Healthcare or Aquillon 16,
Toshiba Medical Systems, Tokyo, Japan).Tissue biopsies
Paired sample biopsies of adipose tissues from 3 com-
partments, namely epicardial, mediastinal, and subcuta-
neous, were taken from the chest of each individual
during surgery. Epicardial adipose tissue (EAT) corre-
sponds to the adipose depot in direct contact with the
heart located between the myocardium and the visceral
pericardium. Mediastinal adipose tissue (MAT) was
defined as the fat deposited in intrathoracic space and
subcutaneous adipose tissue (SAT) as the fat volume
located anterior to the sternum and posterior to the
vertebra. Immediately after resection, approximately
100–300 mg of each fat tissue was snap-frozen in
liquid nitrogen. All tissue samples were then stored
at −80°C until RNA isolation and fatty acid analysis.Total RNA extraction and quantitation
The EAT, MAT and SAT were disrupted with a homogen-
iser in the reaction tube. Total RNA from EAT, MAT
and SAT were extracted with the Allprep kit (Qiagen,
Germany). RNA quantity was determined by Picodrop
(Picodrop, Saffron Walden, UK). After DNase I treatment,
1 μg of RNA was reverse transcribed in 20 μl total volume
using random hexamers and poly(dt) as primers and
Superscript II reverse transcriptase (Invitrogen). Following
cDNA synthesis, the quality of cDNA was assessed by
PCR amplification of the housekeeping gene beta-globin.
cDNA was stored at −80°C until required.Gene expression analysis of 11β-HSD-1, GCR and CD68
mRNA expression levels of 11β-HSD-1, GCR and CD68
were determined by SYBR green-based qRT-PCR using a
LightCycler (Roche-Germany) instrument. Ten fold dilu-
tions of cDNA synthesized from total RNA were used.
All samples were amplified in duplicate and the mean
was obtained for further calculations. Primers were
designed using the software Primer3 v.0.4.0 (http://
frodo.wi.mit.edu/primer3/) and synthesized by TIB-
MOLBIOL (Berlin-Germany).
Immunohistochemical staining
Epicardial, mediastinal and subcutaneous tissue samples
from obese CAD group and control group were studied
in order to demonstrate the presence of CD68 expres-
sion. Epicardial, mediastinal and subcutaneous tissue
samples taken during the operation were immediately
fixed in 10% neutral buffered formalin, then following
the dehydration they were embedded in paraffin. Tissue-
sections (5 μm thick) were taken with microtome (Leica
SM 2000, Germany) on poly-L-lysine-coated slides and
dried at room temperature. The tissue-sections were
then deparaffinized in xylene and rehydrated in graded
alcohol. Zymed Histostain-plus-Peroxidase-kit (Zymed
Laboratoratories Inc.,USA, prepared according to manu-
facturer’s instructions) protocols were applied. Sections
were then washed with distilled water and phosphate
buffered saline (PBS) for 10 minutes and then treated
with 3% H2O2 for 10 minutes to inhibit endogenous per-
oxidase activity. Then, sections were incubated with pri-
mary antibody directed against CD 68 (CD 68, 1:100
dilution; Santa Cruz, Lot#J2207) for 18 hours at 4°C in a
humidity chamber. On the following day, sections were
incubated with biotinylated secondary antibody and then
with streptavidin conjugated to horseradish peroxidase
(both from Zymed Histostain-plus-Peroxidase-kit,
Zymed Laboratoratories Inc.,USA, prepared according to
manufacturer’s instructions). Finally, to reveal the immu-
nolabelling, sections were incubated with AEC Substrate
Kit (Zymed Laboratoratories Inc., USA) for 5 minutes
and then counterstained with Mayer’s hematoxylin and
the samples were photoghraphed by Olympus DP72
model digital microscope cameras.
Determination of free fatty acids in serum and tissues
Fatty acid profiles were prepared by a slight modification
of a method previously described by Yazici et al. [23].
Each sample was weighed and then homogenized in cold
154 mM NaCl. Total lipids and added internal standard
(100 μg nonadecanoic acid in chloroform, Sigma Chem-
ical Co., St.Louis) were extracted with chloroform/
methanol (2:1) containing 0.005% butylated hydroxyto-
luene. The chloroform phase was removed and evapo-
rated to dryness under a stream of nitrogen. Total lipids








Age (years) 57.4 ± 9.1 58.1 ±10.4 NS
Female–male (%) 66-34 51-49 NS
BMI (kg/m2) 33.6 ± 3.1 30.0 ±5.2 NS
Waist/hip ratio 1.1 ± 0.0 0.8 ± 0.1 NS
Risk factors
Smoking (%) 44 66 0.004
Family history of CAD (%) 62 25 0.0001
Metabolic characteristics and indices
SBP (mm Hg) 135.9 ± 19.4 129.5 ± 30.2 NS
DBP (mm Hg) 78.5 ± 8.9 77.3 ± 8.1 NS
Total-cholesterol (mg/dl) 196.1 ± 31.9 200.1 ± 31.4 NS
HDL-cholesterol (mg/dl) 41.2 ± 9.0 45 ± 11.9 NS
LDL-cholesterol (mg/dl) 111.5 ± 19.0 142.4 ± 29.7 0.041
Triglycerides (mg/dl) 191.0 ± 21.5 201.1 ± 24.1 NS
Cortisol (μg/dl) 13.1 ± 4.5 8.2 ± 3.1 0.006
HOMA-IR 3.1 ± 1.6 1.9 ± 1.0 0.005
C-peptid (ng/ml) 2.6 ± 1.1 3.2 ± 1.2 NS
Epicardial fat (cm3) 8.8 ± 5.1 6.0 ± 2.5 0.001
Subcutaneous fat (cm3) 138.8 ± 44.1 133.1 ± 39.1 NS
Values are represented as mean ± SD, or as percentages. SD: Standard
deviation, BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic
blood pressure, HDL: High density lipoprotein, LDL: Low density lipoprotein,
HOMA-IR: Homeostasis Model of Assessment - Insulin Resistance. Groups were
compared with Mann–Whitney U test for the variables.
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acids methylated with hexane and analyzed by capillary
gas chromatography (Perkin-Elmer 8420 Capillary Gas
Chromatography, Gouda, The Netherlands, Column: 50x
0.25 mm WCOT fused silica, CP-sil 88; flame-ionization
detector temperature 300°C; oven temperature from 150
to 230°C at 2°C min-1; carrier gas N2). The mass spectra
of FAME from representative samples were obtained
using a Hewlett Packard (HP) 6890 capillary GC inter-
faced with a HP mass selective detector and controlled
by a HP Chem station (Column: 25x 0.25 mm ID, QC2
x BPx70; detector temperature 280°C; oven temperature
programme from 100°C to 290°C at 3°C min-1; carrier
gas helium).
FAMEs were identified by their retention time and by
comparison with those of authentic standards (Sigma
Chemical Co., St. Louis), and by GC-Mass Spectrometry.
The detector response factors were determined by
injecting equal amounts of fatty acids and internal stand-
ard methyl esters on the column. Their amounts were
estimated by calculating the corresponding areas of fatty
acid and internal standard.
Data analysis
Gene expression data were obtained as Ct values (Ct =
the cycle number at which logarithmic PCR plots cross
a calculated threshold line). Ct values were used to cal-
culate ΔCT values (ΔCT=Ct of the target gene minus
Ct of the housekeeping gene). The expression of each
gene was compared between depots using the ΔΔCt
method. All statistical analysis was performed at the ΔCt
stage in order to exclude potential bias due to averaging
of data transformed through the equation 2-ΔΔCt. Target
gene expression was calculated by using the expression
of a housekeeping gene (cyclophilin) as an internal
standard. The presence of specific gene products was
also confirmed with melting curve analysis. Data are
expressed as numbers and percentages for discrete vari-
ables and as mean ± SD, for continuous variables. Base-
line differences between obese CAD group and controls
were examined by Kruskall Wallis and Mann–Whitney
U test. Variables were compared by Spearman’s correl-
ation to be able to eliminate the effect of outliers. Mul-
tiple linear regression was used to estimate the risk of
increased MAT 11β-HSD-1, GCR and CD68 expression
for developing atherosclerosis in obese patients with
CAD. For the analysis, increased expression levels of
genes in MAT were used as dependent variables and
plasma cortisol, HOMA-IR and stearidonic acid as inde-
pendent variables. These results are reported as coeffi-
cient of determination (R2), which indicates the
percentage of variation in the dependent variable that
can be explained by the independent variables. Statistical
significance was taken as p < 0.05.Results
Patient data
The anthropometric, clinical and metabolic characteris-
tics of obese CAD and control groups are shown in
Table 1. LDL cholesterol (p < 0.05), cortisol (p < 0.05),
HOMA-IR (p < 0.05) and epicardial fat volume
(p < 0.001) were significantly different in obese CAD
group compared with controls. CAD risk factors includ-
ing smoking and family history of CAD were also signifi-
cantly different between groups (p < 0.05 and p < 0.001,
respectively).11β-HSD-1 and GCR expressions in EAT, MAT and SAT
EAT, MAT and SAT depots were assessed for expression
of 11β-HSD-1 and GCR by qRT-PCR in the study group
(Figure 1A). We found that 11β-HSD-1 and GCR mRNA
levels of obese CAD group were significantly higher in
MAT compared to EAT and SAT (p < 0.05, respectively),
and, 11β-HSD-1 mRNA levels in MAT and SAT were
significantly different in obese CAD group compared to
controls (p < 0.05 and p < 0.001, respectively). In
addition, GCR mRNA levels in MAT and SAT were
found to be significantly higher in obese CAD group
Figure 1 The mRNA expression of 11β-HSD1 and GCR in the study groups. A: The mRNA expression of 11β-HSD1 and GCR in 31 obese
patients with CAD (obese CAD group) and 16 obese patients without CAD (control group) in epicardial adipose tissue (EAT), mediastinal adipose
tissue (MAT) and subcutaneous adipose tissue (SAT). *p < 0.05, **p < 0.001 (Obese CAD group vs.control group). Data are mean± SD. B: The mRNA
expression of 11β-HSD1 and GCR in 16 females and 15 males obese patients with CAD in epicardial adipose tissue (EAT), mediastinal adipose
tissue (MAT) and subcutaneous adipose tissue (SAT). * p < 0.05, **p < 0.001 (women vs.men). Data are mean± SD, C: The mRNA expression of
CD68 in 31 obese patients with CAD (obese CAD group) and 16 obese patients without CAD (control group) in epicardial adipose tissue (EAT),
mediastinal adipose tissue (MAT) and subcutaneous adipose tissue (SAT). **p < 0.01 (Obese CAD group vs.control group). Abbreviations: A.U.,
Arbitrary Units.
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more, the expression levels of 11β-HSD-1 and GCR were
further evaluated in both sexes. Men had significantly
higher expression of 11β-HSD-1 and GCR in EAT, MAT
and SAT when compared to women (Figure 1B). 11β-
HSD-1 and GCR gene expression in EAT, MAT and
SAT of females from the controls was no different than
males (data not shown).CD68 mRNA expressions in EAT, MAT and SAT
The significant effect of infiltrating macrophages on adi-
pokine expressions from adipose tissue is well known,
therefore we evaluated mRNA expression of CD68; a
macrophage marker, in EAT, MAT and SAT in both
groups. As shown in Figure 1C, the mRNA levels of
CD68 in MAT and EAT were found to be significantly
higher in obese CAD group compared to controls
(p < 0.05, respectively). MAT CD68 mRNA levels of
obese CAD group were almost two fold higher com-
pared to EAT and SAT. In parallel with mRNA expres-
sion analysis results, the immunohistochemical analysis
also demonstrated the presence of increased CD68+ cells
in MAT of CAD group. Representative photomicro-
graphs showing CD68+ cells stainings in three adiposetissues of obese CAD group and control group are
shown in Figure 2.
The obese CAD patients with a waist circumference
greater than the cut-off values (cut-off points of waist
circumference for cardiovascular disease risk were
87 cm for men and 83 cm for women) had increased
levels of C:18:4n-3, CD68, 11β-HSD-1 and GCR in
MAT (p < 0.05, respectively). In addition, obese CAD
patients with HOMA-IR above the cut-off value of
2.24 showed a strong association with increased CD68
and GCR mRNA levels in EAT and MAT (p < 0.05,
respectively).
Correlations between gene expression levels and
antropometric parameters and fat volumes
Table 2 shows the correlation of 11β-HSD-1 and GCR
mRNA levels in EAT, MAT and SAT depots with study
variables for obese CAD group. A positive correlation
was determined between EAT and MAT GCR mRNA
levels and waist circumference (r = 0.520; p = 0.002,
r = 0.4; p = 0.019) and between SAT GCR mRNA levels
and BMI (r = 0.429; p = 0.009). We demonstrated that
11β-HSD-1 mRNA levels in EAT, MAT and SAT were
positively correlated with weight (r = 0.442; p = 0.006,
r = 0.340; p = 0.027, r = 0,570; p = 0.0001). 11β-HSD-1
Figure 2 Immunohistochemistry using human anti-CD68 for macrophages for epicardial, mediastinal and subcutaneous adipose
tissues of obese CAD and control groups. CD68+ cells (macrophages) are observed in the epicardial, mediastinal and subcutaneous adipose
tissues of obese CAD group (A, B and C) and control group (D, E and F). CD68+ cells (upwards arrow) between normal and large adipocytes
(black asterisks) are identified in the adipose tissues. These findings were endorsed by qRT-PCR of CD68 mRNA expression in all three adipose
tissues of the study group. Magnification: x 40 for A, B, C, D, E and F.
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epicardial fat volume (r = 0.447; p = 0.009). In obese
CAD group, EAT 11β–HSD-1 mRNA expression were
correlated with the expression in MAT and SAT
(r = 0.398; p = 0.015, r = 0.574; p = 0.0001, respectively).
Importantly, a positive correlation was determined be-
tween 11β-HSD-1 and GCR mRNA levels in MAT
(r = 0.529; p = 0.001) (Figure 3).Table 2 Spearman correlation matrix of gene expression of 1
and subcutaneous (SAT) adipose tissues with study variables
Variables 11 β-HSD1 (EAT) 11 β-HSD1 (MAT)
r p r p
Weight 0.442 0.006 0.340 0.027
BMI 0.159 0.363 0.269 0.118
Waist circumference 0.017 0.926 0.244 0.171
Fat (kg) 0.249 0.15 0.248 0.151
Epicardial fat (cm3) 0.447 0.009 0.240 0.179
Subcutaneous fat (cm3) 0.068 0.702 0.207 0.239




GCR (MAT)Fatty acid analysis of serum and adipose tissues
In MAT and EAT, C:18:4n-3 (also known as all-
cis-6,9,12,15,-octadecatetraenoic acid or stearidonic acid)
and n-6/n-3 were found to be significantly higher in
obese CAD group compared controls (p < 0.05) (Table 3).
In EAT only, C:16:1n-7 (palmitoleic acid), C:20:3n-6
(eicosatrienoic acid) and n-3 ratio were also significantly
different between the groups (p < 0.05, respectively). In1β-HSD1 and GCR in epicardial (EAT), mediastinal (MAT)
for obese CAD group (n= 31)
11 β-HSD1 (SAT) GCR (EAT) GCR (MAT) GCR (SAT)
r p r p r p r p
0.570 0.000 0.133 0.666 0.691 0.009 0.492 0.088
0.152 0.384 0.314 0.07 0.317 0.060 0.429 0.009
0.1 0.58 0.520 0.002 0.400 0.019 0.239 0.189
0.233 0.177 0.261 0.135 0.236 0.18 0.285 0.102
0.330 0.061 0.121 0.501 0.146 0.418 0.202 0.256
0.117 0.510 0.207 0.240 0.243 0.167 0.176 0.318
0.574 0.000 0.394 0.018 0.292 0.084 0.381 0.022
0.393 0.016 0.471 0.004 0.529 0.001 0.400 0.16
0.358 0.032 0.374 0.025 0.335 0.046
0.496 0.002 0.389 0.01
0.580 0.000
Figure 3 Scatter plot of 11β-HSD1 versus GCR in mediastinal adipose tissue (MAT) of obese CAD group. Correlation between mRNA
levels of 11β-HSD1 and GCR were assessed using Spearman’s correlation.
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and GCR mRNA levels (r:0.536; p = 0.038, r = 0.682;
p = 0.007, respectively). Furthermore in MAT, 20:4n-6
(arachidonic acid) levels were also significantly higher in
male compared to female obese patients with CAD and
n-6/n-3 ratio was found to be significantly lower in obese
CAD group compared to controls (p < 0.05, respectively).
Linear multiple regression analysis
Analyses were performed to evaluate the relative contri-
bution of biological parameters, related gene expressions
and fatty acids to the relationship with MAT 11β-HSD-
1, GCR and CD68 mRNA levels. The variables explain-
ing the variance of MAT 11β-HSD-1, GCR and CD68
mRNA levels were evaluated in obese CAD group
(Table 4). The analysis showed that the variables plasma
cortisol, HOMA-IR, weight, stearidonic acid and MAT
GCR mRNA levels could explain 40.2% of the variance
in MAT 11β-HSD-1 mRNA levels in obese CAD group.
In addition, MAT 11β-HSD-1 mRNA levels, weight and
cortisol explained 35.1% of the variance in MAT GCR
mRNA levels, MAT 11β-HSD-1, weight and GCR
mRNA levels and cortisol explained 56.4% variance in
MAT CD68 mRNA levels.
The variables explaining the variance of the mRNA
levels of MAT 11β-HSD-1 were evaluated separately in
women and men of the obese CAD group. In men, linearregression analysis with MAT 11β-HSD-1 mRNA level as
the independent variable and plasma cortisol, weight,
HOMA-IR, stearidonic acid and MAT GCR mRNA
levels as the dependent variables showed only MAT GCR
mRNA levels and stearidonic acid significantly explained
the variation of 11β-HSD-1 (β= 0.746, p = 0.003). In
women, none of the variables explained the variance of
the mRNA levels of 11β-HSD-1.
When the effects of age and sex were controlled with
hierarchical multiple regression, MAT GCR mRNA
levels and cortisol remained significant predictors
(β= 0.768, p = 0.009; β= 0.897, p = 0.032, respectively) for
MAT 11β-HSD-1 mRNA levels and they explained
31.2% of the variance in MAT 11β-HSD-1 mRNA levels.
MAT 11β-HSD-1 mRNA levels remained the significant
predictor (β= 0.926, p = 0.009) for MAT GCR mRNA
levels and explained the variance of 28% in MAT GCR
expression. 11β-HSD-1 mRNA expression, GCR mRNA
expression and cortisol remained significant predictors
(β= 0.464, p = 0.005; β= 0.353, p = 0.019; β= 0.450,
p = 0.057, respectively) for MAT CD68 mRNA levels and
they explained the variance of 54.2% of CD68 expression
of obese CAD group.
Discussion
This study examined the relationships between the devel-
opment of atherosclerosis and the two key determinants
Table 3 Fatty acid composition of serum, EAT, MAT and SAT of obese CAD group (n =15) and controls (n = 5)
In SERUM In EAT In MAT In SAT
Fatty acids Obese CAD
group (n = 15)
Controls
(n = 5)
P value Obese CAD
group (n = 15)
Controls
(n = 5)









14:0 (myristic acid) 32.7 ± 4.8 32.3 ± 7.9 NS 9.6 ± 0.8 11.9 ± 1.1 NS 10 ± 0.9 9.7 ± 1.4 NS 10.1 ± 0.7 10.4 ± 0.7 NS
16:0 (palmitic acid) 625.2 ± 99.7 419.6 ± 121.3 NS 108.4 ± 7.1 113.9 ± 10 NS 103.7 ± 5.7 98.3 ± 11.8 NS 105.9 ± 7.1 115.6 ± 6.8 NS
16:1n-7 (palmitoleic acid) 67.1 ± 12.6 51.6 ± 12.7 NS 8.3 ± 0.8 14.6 ± 3.3 0.017 8.9 ± 0.8 6.7 ± 2 NS 10.7 ± 1.2 9.8 ± 2.9 NS
18:0 (stearic acid) 182.8 ± 18.3 169.2 ± 22.8 NS 26.5 ± 1.9 24.6 ± 4.5 NS 23.4 ± 1.6 23.9 ± 4.8 NS 22.5 ± 1.9 24 ± 3.6 NS
18:1n-9 (oleic acid) 671.8 ± 115.3 478.4 ± 71.4 NS 168.4 ± 17.5 172.7 ± 13.5 NS 178 ± 14.5 175.9 ± 18.2 NS 201.2 ± 15 217.6 ± 10.4 NS
18:2n-6 (linoleic acid) 834.7 ± 100.9 727.4 ± 104.3 NS 103.2 ± 6.8 105.8 ± 17.6 NS 106.4 ± 5.5 99.1 ± 17.5 NS 118 ± 8.8 117 ± 11.7 NS
18:3n-3 (linolenic acid) 30.2 ± 6.4 23.3 ± 6.6 NS 1.1 ± 0.3 0.4 ± 0.4 NS 0.6 ± 0.2 0.1 ± 0.1 NS 0.6 ± 0.2 0.2 ± 0.2 NS
18:4n-3 (octatetradecanonic acid) N.D N.D NS 2.8 ± 0.3 1.4 ± 0.6 0.026 2.2 ± 0.4 0.3 ± 0.3 0.026 2.1 ± 0.4 2.1 ± 0.8 NS
20:1n-9 (eicosenoic acid) N.D N.D NS 5.9 ± 0.6 5 ± 0.2 NS 6.6 ± 0.6 5.1 ± 0.8 NS 6 ± 0.5 6 ± 0.6 NS
20:3n-6 (eicosatrienoic acid) 40.3 ± 5.6 42.5 ± 8.3 NS 2.0 ± 0.1 1.3 ± 0.4 0.038 1.6 ± 0.2 1.4 ± 0.3 NS 2.2 ± 0.2 2.3 ± 0.6 NS
20:4n-6 (arachidonic acid) 136.8 ± 18 131± 19.4 NS 2.5 ± 0.3 1.9 ± 0.5 NS 1.7 ± 0.2 1.6 ± 0.3 NS 2.5 ± 0.3 1.8 ± 0.5 NS
20:5n-3 (eicosapentanoic acid) N.D N.D NS N.D N.D NS N.D N.D NS 0.4 ± 0.3 0.2 ± 0,1 NS
22:5n-3 (dokosapentaenoic acid) N.D N.D NS 1.4 ± 0.3 0.9 ± 0.4 NS 1.2 ± 0.3 0.4 ± 0.2 NS 0.6 ± 0.2 0.4 ± 0.2 NS
22:6n-3 (docosahexaenoic acid) N.D N.D NS 2± 0.4 1.3 ± 0.7 NS 2.8 ± 1.7 0.7 ± 0.4 NS 4.4 ± 1.8 1.8 ± 0.6 NS
24:1n-9 (nervonic acid) 25 ± 4.6 33.6 ± 11.4 NS 1.9 ± 0.4 0.6 ± 0.4 NS 1.6 ± 0.4 0.7 ± 0.3 NS 1.6 ± 0.3 1.2 ± 0.4 NS
n-3 (ω− 3) 35 ± 9.5 40.3 ± 9.2 NS 7.5 ± 0.6 4 ± 1.3 0.016 7 ± 1.7 1.6 ± 0.8 NS 8.1 ± 1.9 4.8 ± 0.6 NS
n-6 (ω− 6) 1011.7 ± 115.3 900.9 ± 125.4 NS 107.6 ± 7 109 ± 18.2 NS 109.6 ± 5.7 102 ± 17.7 NS 122.8 ± 9 121.2 ± 12 NS
n-9 (ω− 9) 681.8 ± 116.2 491.8 ± 76.4 NS 176.2 ± 18 178.4 ± 13.9 NS 186.2 ± 15 181.6 ± 19 NS 209 ± 15.2 224.9 ± 10.7 NS
Saturated 840.7 ± 119.9 726.4 ± 107 NS 144.6 ± 9.2 150.3 ± 15.3 NS 137.2 ± 16.9 132 ± 17.7 NS 138.5 ± 9.1 150.1 ± 10.6 NS
Unsaturated 1790.9 ± 237.4 1476.6 ± 205 NS 299.8 ± 20 306 ± 15.3 NS 311.7 ± 16.9 292 ± 36.8 NS 350.4 ± 19 360.5 ± 21 NS
Ratios
16:0 / 16:1 11 ± 1.1 11.1 ± 1.1 NS 14.8 ± 2 10.1 ± 2.7 NS 12.6 ± 0.9 11.8 ± 1.8 NS 11 ± 1 12.6 ± 1.5 NS
18:0 / 18:1 0.3 ± 0.03 0.4 ± 0.05 NS 0.2 ± 0.02 0.14 ± 0.03 NS 0.14 ± 0.02 0.12 ± 0.02 NS 0.11 ± 0.01 0.11 ± 0.01 NS
18:2 / 20:4 6.7 ± 0.7 5.7 ± 0.6 NS 41.3 ± 3.6 47.1 ± 5.6 NS 64.4 ± 6.6 64.5 ± 13.5 NS 49.2 ± 5.3 49.4 ± 4.7 NS
n-6 / n-3 50.3 ± 9.6 24.1 ± 4.4 NS 16.0 ± 1.5 26.8 ± 6.3 0.023 19.5 ± 2.3 43.5 ± 15.4 0.010 19.1 ± 2.3 25.6 ± 4.2 NS
Saturated / Unsaturated 0.5 ± 0.02 0.5 ± 0.02 NS 0.5 ± 0.03 0.5 ± 0.04 NS 0.4 ± 0.02 0.4 ± 0.04 NS 0.4 ± 0.02 0.42 ± 0.03 NS
All values are mean percent of total ± SE. Groups were compared with Mann–Whitney U test for the variables. Significant value, p < 0.05 (Obese CAD group vs. controls). Abbreviations: EAT: epicardial adipose tissue

















Table 4 Predictors of mediastinal adipokines mRNA expression in multiple linear regression analysis
Mediastinaladipokines mRNA expressions Variables R2 Standardized β P Value




GCR mRNA expression Weight 0.351 0.131 0.039
MAT 11β–HSD-1 mRNA levels 0.785 0.005
Cortisol −0.501 0.018
Weight 0.756 0.038
CD68 mRNA expression MAT 11β–HSD-1mRNA levels 0.564 0.480 0.004
MAT GCR mRNA levels 0.351 0.019
Cortisol 0.250 0.031
Weight 0.253 0.065
Multiple linear regression analysis with 11β–HSD-1, GCR and CD68 mRNA expression in mediastinal adipose tissue, cortisol, weight.
HOMA-IR and C:18:4n-3 as dependent variables and mediastinal adipokines mRNA expression in MAT as independent variables.
MAT: mediastinal adipose tissue; GCR: glucocortcoid receptor; C:18:4n-3: stearidonic acid. P < 0.05; statistical significance.
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http://www.cardiab.com/content/11/1/115of tissue glucocorticoid action; 11β-HSD-1 and GCR, in
cardiac fat depots of obese CAD group and controls. The
major findings were; 1) 11β-HSD-1 and GCR mRNA
levels of obese CAD group were significantly higher in
MAT compared to EAT and SAT. In addition, 11β-HSD-
1 and GCR mRNA levels in MAT and SAT were found to
be significantly higher in obese CAD group compared to
controls 2) CD68 mRNA expression was present in MAT
and its expression was significantly higher in MAT
compared to EAT and SAT. 3) MAT 11β-HSD-1 was
positively correlated with MAT GCR mRNA levels in
obese CAD patients 4) In MAT and EAT, stearidonic
acid was significantly higher in obese CAD group
compared to controls. And, in addition stearidonic acid
in MAT was correlated with 11β-HSD-1 and GCR
mRNA levels 5) Arachidonic acid was significantly
higher in obese male CAD patients 6) Plasma cortisol
was significantly increased in obese CAD group com-
pared to controls. The regression analysis revealed that
the interrelation between plasma cortisol, weight, stear-
idonic acid, MAT GCR mRNA levels along with
HOMA-IR could explain 40.2% of the variance in
MAT 11β-HSD-1 mRNA levels (dependent variable) in
obese CAD group.
Expression of adipokines and inflammatory cytokines are
altered in MAT
The recent insight that visceral fat contributes to the de-
velopment of atherosclerosis constitutes a major break-
through in understanding the mechanisms underlying
these conditions. It is well known that glucocorticoids can
influence the development of cardiovascular disease al-
though the process is complex. Glucocorticoids possess a
wide range of functions including the stimulation of both
glucocorticoid and mineralocorticoid receptors [24], themediation of opposing actions depending on steroid con-
centration, and the regulation of systemic cardiovascular
risk factors as well as the functional and structural prop-
erties of cardiac, vascular and inflammatory cells. This
contributes to the difficulty in determining which of these
mechanisms involving glucocorticoids contributes to the
regulation of cardiovascular disease pathogenesis. 11β-
HSD-1 is widely expressed, particularly in liver, adipose
tissue, brain, lung, gonads and adrenal cortex [15]. Previ-
ous studies suggested that 11β-HSD-1 has an important
role in regulating the HPA axis due to its ability of locally
amplify glucocorticoids, and its expression in areas known
to be relevant to glucocorticoid regulation of HPA axis
control. Transgenic mice overexpressing 11β-HSD-1 in
adipose tissue develop visceral obesity, insulin resistance,
hyperglycemia, dyslipidemia, and hypertension [17]. Glo-
bal deletion of 11β-HSD-1 caused reduced visceral fat ac-
cumulation and these mice had improved insulin
sensitivity on a high fat diet [25,26]. In humans, 11β-
HSD-1 gene expression in cardiac adipose tissue samples
showed the important role of EAT compared with SAT in
CAD by inducing local cortisol reactivation [27]. An in-
crease in GCR expression in epicardial fat was reported in
obesity and CAD, possibly leading to an amplification of
glucocorticoid signaling and growth of this ectopic fat
depot [20]. Other studies also demonstrated that visceral
adipose tissues expressed high levels of 11β-HSD-1 in
obese CAD group, and this is known to be positively
associated with metabolic risk factors and CAD [10]. Two
studies demonstrated 11β-HSD-1 activity in intact frag-
ments of human omental fat was significantly correlated
with visceral fat mass [28,29]. In light of these previous
findings, we have investigated the contributory role of the
expression of 11β-HSD-1 and GCR in two cardiac visceral
fat depots EAT and MAT, in comparison with SAT in the
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Firstly, we confirm the role of visceral fat depots, espe-
cially MAT, in the development of cardiovascular diseases
[7]. In addition, we determined a positive correlation be-
tween 11β-HSD-1 and GCR gene expression in MAT of
obese CAD patients, which would imply an upregulation
of glucocorticoid production through 11β-HSD-1 in
MAT possibly resulting in an increased volume of MAT
in obese CAD patients compared to controls. Although,
previous studies reported the altered expressions of the
inflammatory adipocytokines (TNF-α, IL-6, leptin and
chemerine and adiponectin) in EAT of CAD [30-32], a
strong association of MAT and CAD was recently
reported by various researchers, and, MAT became the
most reliable marker for the cardiometabolic risk [6].
Therefore gene expression results demonstrating
increased 11β-HSD-1, GCR, CD68, and inflammation in
MAT of obese CAD group might strengthen and contrib-
ute to the recently demonstrated MRI data suggesting
that MAT volume is a better predictor for CAD com-
pared to other visceral fat depots. Despite the fact that
MAT is not close to the coronary arteries, it constitutes
the majority of cardiac fat, therefore it is far from being
just an inner compartment of intrathoracic fat. Medias-
tinal adipose tissue (paracardial or intrathoracic) constitu-
tes the majority of cardiac fat accumulation (70%), with
EAT constituting approximately 30%. Paracardial fat vol-
ume was reported to be nearly twice as high in CAD
patients with high-risk coronary lesions as compared to
those without CAD, and it was significantly associated
with high risk coronary lesion morphology independent
of clinical characteristics and general obesity [33,34]. The
correlation of intrathoracic and pericardial fat with body
mass index and vascular calcification and their association
with the presence and severity of coronary artery calcium
were also demonstrated [10,35]. In a recent study per-
formed with obese healthy volunteers, increased cardiac
fat in MAT (pericardial area) was strongly associated with
features of the metabolic syndrome, whereas no correl-
ation was found with EAT [6], and in another study EAT
thickness was shown to be useful to predict MS and CAD
in patients with BMI< 27 kg/m2 but not in obese patients
[36]. Alltogether these results indicate the prevalent role
of MAT rather than EAT in better diagnosis of cardiome-
tabolic risk in obese patients. Along with the adipokines,
increased levels of FFA and the recruitment of macro-
phages into the adipose tissues were shown to stimulate
the inflammation and to impair some transcriptional cas-
cades which eventually lead to the formation of coronary
atherosclerosis [37-40]. Therefore, we investigated the
correlations of macrophage infiltration and the fatty acids
with the gene expressions in visceral fat depots. With the
use of CD68 as a macrophage marker, we demonstrated
that expression levels of CD68 in EAT and MAT weresignificantly higher in obese CAD group compared to
controls (Figure 1C), and also MAT CD68 was signifi-
cantly higher compared to EAT and SAT in obese CAD
group. In this study, we confirm the presence of macro-
phage infiltration in EAT of CAD patients which was pre-
viously demonstrated by Hirata et al. [11]. Furthermore,
as a new finding, we demonstrated the increased gene ex-
pression of CD68 in MAT by qRT-PCR and the immuno-
histochemical staining which would clearly indicate the
presence of infiltrating macrophages in this visceral fat in
obese CAD group. As the expression is higher compared
to EAT and SAT, one might expect a high number of
infiltrated macrophages into MAT, and this is quite pos-
sible as MAT constitutes the largest volume of the cardiac
adipose tissue. Interestingly, in females of obese CAD
group, 11β-HSD-1 expression in MAT was strongly cor-
related with GCR expression and plasma cortisol was
found to be positively correlated with 11β-HSD-1 expres-
sion. Subtle changes in cortisol were previously reported
to be present in obesity. In particular, 11β-HSD-1 was
shown to result in higher intraadipose cortisol levels in
obese subjects [41], although some studies reported the
opposite [42]. Although not statistically significant, corti-
sol levels were found to be higher in women of obese
CAD group compared with men (Data not shown). It was
previously described that the cortisol stimulates the min-
eralocorticoid receptor (MR) in obese patients and in
patients with Cushing’s disease via a mechanism involving
the saturation of the enzyme 11 hydroxysteroid dehydro-
genase. In addition MRs facilitate the expression of in-
flammatory adipokines and stimulate the proadipogenic
effects of glucocorticoid and aldosterone. The inhibition
of these receptors increase the expression adiponectin in
heart and adipose tissues. To understand the role of
increased cortisol on the expression of MR and the asso-
ciated inflammatory cytokines, we have further studied
the mRNA levels of MR along with TNF-α, IL-6 and adi-
ponectin in EAT, MAT and SAT. The results showed that
MR mRNA levels were significant increased only in EAT
and MAT of obese CAD group compared to controls.
There were significant differences in TNF-α, IL-6 and adi-
ponectin mRNA levels between EAT, MAT and SAT of
obese CAD group compared to controls (Figure 4). TNF-
α and IL-6 were significantly increased in obese CAD
group compared to controls, though adiponectin was
found to be significantly decreased. These additional find-
ings might suggest that increased cortisol may also inter-
act with MR. In the presence of steroids (aldosterone or
glucocorticoids) they would increase the visceral adipo-
genesis and macrophage infiltration which are known to
be the two essential factors in the development of inflam-
mation in the adipose tissue.
Further analysis of the patient group revealed that the
expression of 11β-HSD-1 and GCR in EAT, MAT and
Figure 4 The mRNA expression of Mineralocorticoid Receptor (MR) and TNF-α, IL-6 and adiponectin in 31 obese patients with CAD
(obese CAD group) and 16 obese patients without CAD (control group) in epicardial adipose tissue (EAT), mediastinal adipose tissue
(MAT) and subcutaneous adipose tissue (SAT). *p < 0.05, **p < 0.001 (Obese CAD group vs.controls). Data are mean± SD.
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http://www.cardiab.com/content/11/1/115SAT depots was higher in obese CAD group in both
women and men. However the expression of 11β-HSD-1
and GCR in SAT was found to be significantly higher in
the male obese CAD group when compared with
women. This is also in concordance with Paulsen et al.
who reported the effects of gender and sex hormones on
11β-HSD-1 expression in human adipose tissue [43].
Fatty acids and cardiac adipose tissues: steraridonic acid
is positively correlated with mediastinal 11β-HSD-1
expression
Our analysis of fatty acid levels in serum and adipose tis-
sues revealed that stearidonic acid and the n-6/n-3 ratio
in EAT and MAT, and palmitoleic acid, eicosatrienoic acid
and n-3 in EAT were significantly different in obese CAD
group compared to controls. Previous studies have
reported that eicosapentaenoic acid supplementation can
reduce the risk of coronary heart disease and that it can
be synthesized from α-linolenic acid (C18:3n-3) via the
conversion of the Δ6-desaturation of α-linolenic acid into
stearidonic acid. Interestingly, in EAT and MAT, controls
showed significantly lower levels of stearidonic acid com-
pared to obese patients with CAD, moreover arachidonic
acid levels were significantly higher in male compared
with female obese CAD patients in MAT. Interestingly,the significant expression of genes related with the arachi-
donic pathway in EAT was recently reported in a whole-
genome gene expression microarray analysis of the EAT,
MAT and SAT of six male patients suffering from CAD
[44]. Our results confirm the expression of arachidonic
acid in EAT and show for the first time its significant ex-
pression in MAT of obese male CAD patients. In EAT,
palmitoleic acid was found to be positively correlated with
GCR mRNA expression and in MAT, stearidonic acid
strongly correlated with waist circumference and 11β-
HSD-1 MAT. Recently, Vara Prasad et al. showed that, in
rats, trans fatty acids and saturated fatty acids increase
local amplification of glucocorticoid activity in adipose
tissue and that this increase occurs by upregulation of
11β-HSD1 following changes in the expression of its main
transcription factor C/EBP-α [45]. In obese CAD patients,
we confirm increased presence of stearidonic acid and
arachidonic acid in cardiac visceral fat.
Together, our findings demonstrate that MAT is
closely associated with 11β-HSD-1 mRNA expression in
obese CAD group. Interestingly, our findings also sug-
gest that inflammatory cell infiltration is enhanced in
the MAT of obese patients with CAD, highlighting the
influential role of chronic inflammation in MAT on the
pathogenesis of coronary atherosclerosis.
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positive correlation between 11β-HSD-1 and GCR in
MAT, and it seems likely that 11β-HSD-1 and GCR dir-
ectly regulate each other. The regression analysis results
revealed that GCR mRNA levels in MAT, cortisol, steari-
donic acid and HOMA-IR explained 40.2% of the vari-
ance in 11β-HSD-1 mRNA levels in MAT, while MAT
11β-HSD-1 mRNA levels and cortisol explained 35.1%
of the variance in MAT GCR mRNA levels, MAT 11β-
HSD-1 and GCR mRNA levels and cortisol explained
56.4% variance in MAT CD68 mRNA levels. Along with
the increased cortisol levels, expression of MR and the
inflammatory cytokines were also found to be increased
whereas the expression of adiponectin was decreased in
MAT of obese CAD group. These results may also pro-
vide insight into the biology of MAT and potentially
suggest a degree of cross-talk between glucocorticoid
action, cortisol, fatty acids, macrophages, inflammation
and mediastinal adipose tissue in obese CAD group.
The differential expression of fatty acids in adipose tis-
sues, especially stearidonic acid in EAT and MAT, may
reflect differences in the functional mechanisms of fatty
acid transporters in each adipose tissue, and therefore
our preliminary results might well be used in future
studies to determine these mechanisms.
Conclusion
In conclusion, we report for the first time increased ex-
pression of 11β-HSD-1, GCR and CD68 in MAT and
also demonstrated the interrelated effects of biological
parameters, fatty acids, along with related gene expres-
sions to explain the variance of 11β-HSD-1, GCR and
CD68 expressions in MAT of obese CAD patients.
These findings support the hypothesis that MAT contri-
butes locally to the development of coronary athero-
sclerosis via the glucocorticoid action.
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